TriangleREPLAY (NCT07237594)
REPLAY trial for Metastatic Melanoma After Immune-Related Toxicity (NCT07237594). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic melanoma who have already received immune checkpoint inhibitor therapy and had an immune related side effect.
The idea: give secukinumab, an IL-17A antibody injected under the skin, while restarting checkpoint inhibitor therapy. The study looks at whether blocking IL-17 is safe and feasible in this setting.
This phase 1 study plans 4 patients. At Duke University, April Salama leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.